Published in BMC Complement Altern Med on April 30, 2008
The effects of beta-glucan on human immune and cancer cells. J Hematol Oncol (2009) 1.88
Complementary and alternative medicines use by Scottish women with breast cancer. What, why and the potential for drug interactions? Eur J Clin Pharmacol (2011) 1.62
Characteristics of health information gatherers, disseminators, and blockers within families at risk of hereditary cancer: implications for family health communication interventions. Am J Public Health (2009) 1.57
Associations of herbal and specialty supplements with lung and colorectal cancer risk in the VITamins and Lifestyle study. Cancer Epidemiol Biomarkers Prev (2009) 1.14
Use of Chinese medicine by cancer patients: a review of surveys. Chin Med (2011) 0.95
Use of multivitamins, folic acid and herbal supplements among breast cancer survivors: the black women's health study. BMC Complement Altern Med (2011) 0.93
The Relationship between Complementary and Alternative Medicine Use and Breast Cancer Early Detection: A Critical Review. Evid Based Complement Alternat Med (2012) 0.78
Hot flashes severity, complementary and alternative medicine use, and self-rated health in women with breast cancer. Explore (NY) (2014) 0.76
A single-center, randomized double-blind placebo-controlled study evaluating the effects of poly-gamma-glutamate on human NK cell activity after an 8-week oral administration in healthy volunteers. Evid Based Complement Alternat Med (2013) 0.75
Adverse events associated with complementary and alternative medicine use in ovarian cancer patients. Integr Cancer Ther (2013) 0.75
High use of complementary and alternative medicine among a large cohort of women with a family history of breast cancer: the Sister Study. Breast Cancer Res Treat (2016) 0.75
Diet and predictors of dietary intakes in women with family history of breast and/or ovarian cancer. Cancer Epidemiol (2009) 0.75
Expectations from an integrative medicine consultation in breast cancer care: a registry protocol-based study. Support Care Cancer (2014) 0.75
Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA (1998) 35.46
Complementary and alternative medicine use among adults: United States, 2002. Adv Data (2004) 17.17
Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol (2000) 5.48
Psychological side effects of breast cancer screening. Health Psychol (1991) 3.30
Alternative therapies used by women with breast cancer in four ethnic populations. J Natl Cancer Inst (2000) 2.87
Attitudes about genetic testing for breast-ovarian cancer susceptibility. J Clin Oncol (1994) 2.52
Use of complementary medicine by adult patients participating in cancer clinical trials. Oncol Nurs Forum (2000) 2.41
Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med (2000) 2.39
Trends in complementary/alternative medicine use by breast cancer survivors: comparing survey data from 1998 and 2005. BMC Womens Health (2007) 2.24
Use of complementary and alternative medicine and prayer among a national sample of cancer survivors compared to other populations without cancer. Complement Ther Med (2006) 1.85
Use of alternative therapies for menopause symptoms: results of a population-based survey. Obstet Gynecol (2002) 1.75
Use of complimentary and alternative medicine by breast cancer patients: prevalence, patterns and communication with physicians. Support Care Cancer (2002) 1.63
A comparison of complementary therapy use between breast cancer patients and patients with other primary tumor sites. Am J Surg (2000) 1.62
Prevention and management of hereditary breast cancer. J Clin Oncol (2005) 1.55
Complementary and alternative medicine use among American women: findings from The National Health Interview Survey, 2002. J Womens Health (Larchmt) (2007) 1.46
Prevalence and treatment of menopausal symptoms among breast cancer survivors. J Pain Symptom Manage (2002) 1.40
Complementary and alternative medicine use among breast cancer survivors. J Altern Complement Med (2007) 1.38
Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing. J Clin Oncol (2003) 1.38
Breast cancer patients' perspectives on and use of complementary and alternative medicine: a study by the Susan G. Komen Breast Cancer Foundation. J Soc Integr Oncol (2006) 1.37
The use of complementary and alternative medicines among patients with locally advanced breast cancer--a descriptive study. BMC Cancer (2006) 1.30
Missing data on the Center for Epidemiologic Studies Depression Scale: a comparison of 4 imputation techniques. Res Social Adm Pharm (2007) 1.27
Complementary and alternative medicine use is associated with an increased perception of breast cancer risk and death. Breast Cancer Res Treat (2005) 1.08
Attitudes to prophylactic surgery and chemoprevention in Australian women at increased risk for breast cancer. J Womens Health (Larchmt) (2003) 1.05
Safety issues in using complementary and alternative medicine. J Clin Oncol (2002) 1.03
Complementary medicine use among women enrolled in a genetic testing program. Cancer Epidemiol Biomarkers Prev (2003) 0.91
Complementary medicine use before and 1 year following genetic testing for BRCA1/2 mutations. Cancer Epidemiol Biomarkers Prev (2006) 0.89
Depression and the use of complementary medicine among breast cancer patients. Support Care Cancer (2004) 0.89
Behavioral risk factors among women presenting for genetic testing. Cancer Epidemiol Biomarkers Prev (2000) 0.87
Attitudes toward prophylactic oophorectomy and screening utilization in women at increased risk of developing hereditary breast/ovarian cancer. Gynecol Oncol (1999) 0.84
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Cancer incidence in persons with Fanconi anemia. Blood (2002) 4.05
Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. Blood (2007) 3.86
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA (2012) 3.85
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet (2007) 3.63
Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum (2002) 3.63
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol (2005) 3.25
Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br J Haematol (2010) 3.09
The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med (2009) 2.91
Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst (2006) 2.42
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
Competing risks analysis of correlated failure time data. Biometrics (2007) 2.31
Concise handbook of familial cancer susceptibility syndromes - second edition. J Natl Cancer Inst Monogr (2008) 2.29
The Y deletion gr/gr and susceptibility to testicular germ cell tumor. Am J Hum Genet (2005) 2.26
Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. Hum Mol Genet (2006) 2.23
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13
Confirmation of family cancer history reported in a population-based survey. J Natl Cancer Inst (2011) 2.13
Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. J Clin Oncol (2005) 2.11
Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers. Breast Cancer Res Treat (2014) 2.10
Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev (2011) 1.99
Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns (2011) 1.92
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genet (2013) 1.88
Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155. Nat Med (2011) 1.79
AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. Cancer Epidemiol Biomarkers Prev (2007) 1.75
Meta-analysis identifies four new loci associated with testicular germ cell tumor. Nat Genet (2013) 1.74
Variants in or near KITLG, BAK1, DMRT1, and TERT-CLPTM1L predispose to familial testicular germ cell tumour. J Med Genet (2011) 1.73
The International Testicular Cancer Linkage Consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. Urol Oncol (2009) 1.70
Cancer in Fanconi anemia. Blood (2003) 1.63
Characteristics of health information gatherers, disseminators, and blockers within families at risk of hereditary cancer: implications for family health communication interventions. Am J Public Health (2009) 1.57
Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. PLoS Genet (2010) 1.56
A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study. Cancer Epidemiol Biomarkers Prev (2008) 1.52
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2011) 1.51
All in the family: disclosure of "unwanted" information to an adolescent to benefit a relative. Am J Med Genet A (2008) 1.44
Familial testicular germ cell tumors in adults: 2010 summary of genetic risk factors and clinical phenotype. Endocr Relat Cancer (2010) 1.41
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2010) 1.41
Cancer risk among patients with myotonic muscular dystrophy. JAMA (2011) 1.38
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res (2012) 1.38
Comparing breast cancer risk assessment models. J Natl Cancer Inst (2010) 1.35
Functional phosphodiesterase 11A mutations may modify the risk of familial and bilateral testicular germ cell tumors. Cancer Res (2009) 1.35
Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers? Am J Obstet Gynecol (2010) 1.27
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res (2011) 1.22
Hypothesis: neoplasms in myotonic dystrophy. Cancer Causes Control (2009) 1.22
Dyskeratosis congenita: the first NIH clinical research workshop. Pediatr Blood Cancer (2009) 1.22
Challenges related to developing serum-based biomarkers for early ovarian cancer detection. Cancer Prev Res (Phila) (2011) 1.19
Testicular germ cell tumor susceptibility associated with the UCK2 locus on chromosome 1q23. Hum Mol Genet (2013) 1.19
Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2012) 1.17
Potential usefulness of single nucleotide polymorphisms to identify persons at high cancer risk: an evaluation of seven common cancers. J Clin Oncol (2012) 1.15
Use of an educational computer program before genetic counseling for breast cancer susceptibility: effects on duration and content of counseling sessions. Genet Med (2005) 1.13
LINE-1 methylation is inherited in familial testicular cancer kindreds. BMC Med Genet (2010) 1.11
Familial and genetic risk of transitional cell carcinoma of the urinary tract. Urol Oncol (2008) 1.11
Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. Cancer Prev Res (Phila) (2011) 1.10
Sisters in hereditary breast and ovarian cancer families: communal coping, social integration, and psychological well-being. Psychooncology (2008) 1.05
Analysis of the DND1 gene in men with sporadic and familial testicular germ cell tumors. Genes Chromosomes Cancer (2008) 1.05
Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium. Cancer Genet (2012) 1.04
Referral to cancer genetic counseling: are there stages of readiness? Am J Med Genet C Semin Med Genet (2006) 1.02
A mini-review of familial ovarian germ cell tumors: an additional manifestation of the familial testicular germ cell tumor syndrome. Cancer Epidemiol (2009) 1.02
Relationships between computer-extracted mammographic texture pattern features and BRCA1/2 mutation status: a cross-sectional study. Breast Cancer Res (2014) 1.02
Ductal lavage in women from BRCA1/2 families: is there a future for ductal lavage in women at increased genetic risk of breast cancer? Cancer Epidemiol Biomarkers Prev (2009) 1.01
Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2010) 1.01
Mammographic density does not differ between unaffected BRCA1/2 mutation carriers and women at low-to-average risk of breast cancer. Breast Cancer Res Treat (2010) 1.00
Ovarian cancer screening in women with a family history of breast or ovarian cancer. Obstet Gynecol (2006) 0.99
Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Hum Mutat (2012) 0.98